Skip to main content

Articles

Page 1 of 65

  1. Ovarian cancer is the leading cause of gynecological cancer-related death. Drug resistance is the bottleneck in ovarian cancer treatment. The increasing use of novel drugs in clinical practice poses challenges...

    Authors: Ling Wang, Xin Wang, Xueping Zhu, Lin Zhong, Qingxiu Jiang, Ya Wang, Qin Tang, Qiaoling Li, Cong Zhang, Haixia Wang and Dongling Zou
    Citation: Molecular Cancer 2024 23:66
  2. Abnormal angiogenesis is crucial for gallbladder cancer (GBC) tumor growth and invasion, highlighting the importance of elucidating the mechanisms underlying this process. LncRNA (long non-coding RNA) is widel...

    Authors: Zhiqiang He, Yuhan Zhong, Parbatraj Regmi, Tianrun Lv, Wenjie Ma, Junke Wang, Fei Liu, Siqi Yang, Yanjie Zhong, Rongxing Zhou, Yanwen Jin, Nansheng Cheng, Yujun Shi, Haijie Hu and Fuyu Li
    Citation: Molecular Cancer 2024 23:65
  3. Previous studies have shown the clinical benefit of rechallenging the RAF pathway in melanoma patients previously treated with BRAF inhibitors. 44 patients with multiple tumors harboring RAF alterations were rech...

    Authors: Blessie Elizabeth Nelson, Jason Roszik, Jibran Ahmed, Carmelia Maria Noia Barretto, Mirella Nardo, Erick Campbell, Amber M Johnson, Sarina A. Piha-Paul, Isabella C. Glitza Oliva, Shiao-Pei Weathers, Maria Cabanillas, Milind Javle, Funda Meric-Bernstam and Vivek Subbiah
    Citation: Molecular Cancer 2024 23:64
  4. Efficient predictive biomarkers are needed for immune checkpoint inhibitor (ICI)-based immunotherapy in non-small cell lung cancer (NSCLC). Testing the predictive value of single nucleotide polymorphisms (SNPs...

    Authors: Giovanna Polcaro, Luigi Liguori, Valentina Manzo, Annalisa Chianese, Giuliana Donadio, Alessandro Caputo, Giosuè Scognamiglio, Federica Dell’Annunziata, Maddalena Langella, Graziamaria Corbi, Alessandro Ottaiano, Marco Cascella, Francesco Perri, Margot De Marco, Jessica Dal Col, Giovanni Nassa…
    Citation: Molecular Cancer 2024 23:63
  5. While strategies such as chemotherapy and immunotherapy have become the first-line standard therapies for patients with advanced or metastatic cancer, acquired resistance is still inevitable in most cases. The...

    Authors: Kaifeng Liu, Meijia Li, Yudong Li, Yutong Li, Zixin Chen, Yiqi Tang, Meitian Yang, Guoquan Deng and Hongwei Liu
    Citation: Molecular Cancer 2024 23:62
  6. Immuno-radiotherapy may improve outcomes for patients with advanced solid tumors, although optimized combination modalities remain unclear. Here, we report the colorectal (CRC) cohort analysis from the SABR-PD...

    Authors: Antonin Levy, Daphné Morel, Matthieu Texier, Roger Sun, Jerome Durand-Labrunie, Maria E Rodriguez-Ruiz, Severine Racadot, Stéphane Supiot, Nicolas Magné, Stacy Cyrille, Guillaume Louvel, Christophe Massard, Loic Verlingue, Fanny Bouquet, Alberto Bustillos, Lisa Bouarroudj…
    Citation: Molecular Cancer 2024 23:61
  7. Cancer stem-like cell is a key barrier for therapeutic resistance and metastasis in various cancers, including breast cancer, yet the underlying mechanisms are still elusive. Through a genome-wide lncRNA expre...

    Authors: Fei Luo, Mingda Zhang, Bowen Sun, Chenxin Xu, Yi Yang, Yingwen Zhang, Shanshan Li, Guoyu Chen, Ceshi Chen, Yanxin Li and Haizhong Feng
    Citation: Molecular Cancer 2024 23:60
  8. Tyrosine kinase inhibitors (TKIs) are crucial in the targeted treatment of advanced colorectal cancer (CRC). Anlotinib, a multi-target TKI, has previously been demonstrated to offer therapeutic benefits in pre...

    Authors: Haosheng Li, Haoran Feng, Tao Zhang, Junwei Wu, Xiaonan Shen, Shuiyu Xu, Lianghui Xu, Shaodong Wang, Yaqi Zhang, Wenqing Jia, Xiaopin Ji, Xi Cheng and Ren Zhao
    Citation: Molecular Cancer 2024 23:59
  9. Cytotoxic T lymphocytes (CTLs) play critical antitumor roles, encompassing diverse subsets including CD4+, NK, and γδ T cells beyond conventional CD8+ CTLs. However, definitive CTLs biomarkers remain elusive, ...

    Authors: Shengkun Peng, Anqi Lin, Aimin Jiang, Cangang Zhang, Jian Zhang, Quan Cheng, Peng Luo and Yifeng Bai
    Citation: Molecular Cancer 2024 23:58
  10. Urine-based testing is promising for noninvasive diagnosis of urothelial carcinoma (UC) but has suboptimal sensitivity for early-stage tumors. Herein, we developed a multitarget urine tumor DNA test, UI-Seek, ...

    Authors: Junlong Wu, Yuda Lin, Kaiwei Yang, Xiao Liu, Huina Wang, Tingting Yu, Ran Tao, Jing Guo, Libin Chen, Huanqing Cheng, Feng Lou, Shanbo Cao, Wei Yu, Hailong Hu and Dingwei Ye
    Citation: Molecular Cancer 2024 23:57
  11. One of the major hurdles that has hindered the success of chimeric antigen receptor (CAR) T cell therapies against solid tumors is on-target off-tumor (OTOT) toxicity due to sharing of the same epitopes on nor...

    Authors: Yufei Wang, Alicia Buck, Brandon Piel, Luann Zerefa, Nithyassree Murugan, Christian D. Coherd, Andras G. Miklosi, Haraman Johal, Ricardo Nunes Bastos, Kun Huang, Miriam Ficial, Yasmin Nabil Laimon, Sabina Signoretti, Zhou Zhong, Song-My Hoang, Gabriella M. Kastrunes…
    Citation: Molecular Cancer 2024 23:56
  12. Long noncoding RNAs (lncRNAs) have emerged as key players in tumorigenesis and tumour progression. However, the biological functions and potential mechanisms of lncRNAs in colorectal cancer (CRC) are unclear.

    Authors: Tao Jiang, Junwen Qi, Zhenyu Xue, Bowen Liu, Jianquan Liu, Qihang Hu, Yuqiu Li, Jing Ren, Hu Song, Yixin Xu, Teng Xu, Ruizhi Fan and Jun Song
    Citation: Molecular Cancer 2024 23:55
  13. Phosphoinositide 3-kinases (PI3Ks) are critical regulators of diverse cellular functions and have emerged as promising targets in cancer therapy. Despite significant progress, existing PI3K inhibitors encounte...

    Authors: Xin Peng, Xin Huang, Talal Ben Lulu, Wenqing Jia, Shaolu Zhang, Limor Cohen, Shengfan Huang, Jindian Fan, Xi Chen, Shanshan Liu, Yongzhe Wang, Kailin Wang, Sho Isoyama, Shingo Dan, Feng Wang, Zhe Zhang…
    Citation: Molecular Cancer 2024 23:54
  14. Chimeric antigen receptor-T (CAR-T) cells therapy is one of the novel immunotherapeutic approaches with significant clinical success. However, their applications are limited because of long preparation time, h...

    Authors: Tao Chen, Jieyi Deng, Yongli Zhang, Bingfeng Liu, Ruxin Liu, Yiqiang Zhu, Mo Zhou, Yingtong Lin, Baijin Xia, Keming Lin, Xiancai Ma and Hui Zhang
    Citation: Molecular Cancer 2024 23:53
  15. Polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) is one of the causes of tumor immune tolerance and failure of cancer immunotherapy. Here, we found that bladder cancer (BCa)-derived exosomal circ...

    Authors: Xiaojun Shi, Shiyu Pang, Jiawei Zhou, Guang Yan, Ruxi Gao, Haowei Wu, Zhou Wang, Yuqing Wei, Xinyu Liu and Wanlong Tan
    Citation: Molecular Cancer 2024 23:52
  16. Despite advancements in treatment protocols, cancer is one of the leading cause of deaths worldwide. Therefore, there is a need to identify newer and personalized therapeutic targets along with screening techn...

    Authors: Anmi Jose, Pallavi Kulkarni, Jaya Thilakan, Murali Munisamy, Anvita Gupta Malhotra, Jitendra Singh, Ashok Kumar, Vivek M. Rangnekar, Neha Arya and Mahadev Rao
    Citation: Molecular Cancer 2024 23:50
  17. Circular RNAs (circRNAs) play important roles in gastric cancer progression but the regulatory role of circRNAs in controlling macrophage function remains elusive. Exosomes serve as cargo for circRNAs and play...

    Authors: Cuncan Deng, Mingyu Huo, Hongwu Chu, Xiaomei Zhuang, Guofei Deng, Wenchao Li, Hongfa Wei, Leli Zeng, Yulong He, Huashan Liu, Jia Li, Changhua Zhang and Hengxing Chen
    Citation: Molecular Cancer 2024 23:49
  18. Pancreatic adenocarcinoma (PC) is an aggressive malignancy with limited treatment options. The poor prognosis primarily stems from late-stage diagnosis and when the disease has become therapeutically challengi...

    Authors: Weiyu Ge, Yanling Wang, Ming Quan, Tiebo Mao, Evelyne Y. Bischof, Haiyan Xu, Xiaofei Zhang, Shumin Li, Ming Yue, Jingyu Ma, Haiyan Yang, Lei Wang, Zhengyuan Yu, Liwei Wang and Jiujie Cui
    Citation: Molecular Cancer 2024 23:48
  19. Cancer-associated fibroblasts (CAFs) orchestrate a supportive niche that fuels cancer metastatic development in non-small cell lung cancer (NSCLC). Due to the heterogeneity and plasticity of CAFs, manipulating...

    Authors: Yan Zhao, Yunlong Jia, Jiali Wang, Xiaolin Chen, Jingya Han, Shuman Zhen, Shuxian Yin, Wei Lv, Fan Yu, Jiaqi Wang, Fan Xu, Xinming Zhao and Lihua Liu
    Citation: Molecular Cancer 2024 23:47
  20. Nucleic acid vaccines have shown promising potency and efficacy for cancer treatment with robust and specific T-cell responses. Improving the immunogenicity of delivered antigens helps to extend therapeutic ef...

    Authors: Hailong Qi, Zhongjie Sun, Tianle Gao, Yanling Yao, Yu Wang, Weiwei Li, Xudong Wang, Xiaofang Wang, Defang Liu and Jian-Dong Jiang
    Citation: Molecular Cancer 2024 23:46
  21. In the myeloid compartment of the tumor microenvironment, CD244 signaling has been implicated in immunosuppressive phenotype of monocytes. However, the precise molecular mechanism and contribution of CD244 to ...

    Authors: Jeongsoo Kim, Tae-Jin Kim, Sehyun Chae, Hyojeong Ha, Yejin Park, Sunghee Park, Chul Joo Yoon, Seon Ah Lim, Hyemin Lee, Jiyoung Kim, Jungwon Kim, Kyungtaek Im, Kyunghye Lee, Jeongmin Kim, Daham Kim, Eunju Lee…
    Citation: Molecular Cancer 2024 23:45
  22. Authors: Mohammad Chehelgerdi, Matin Chehelgerdi, Milad Khorramian‑Ghahfarokhi, Marjan Shafieizadeh, Esmaeil Mahmoudi, Fatemeh Eskandari, Mohsen Rashidi, Asghar Arshi and Abbas Mokhtari‑Farsani
    Citation: Molecular Cancer 2024 23:43

    The original article was published in Molecular Cancer 2024 23:9

  23. Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma. A major mutagenic process in DLBCL is aberrant somatic hypermutation (aSHM) by activation-induced cytidine deaminase (AID), which occurs prefe...

    Authors: Maria S. Benitez-Cantos, Carlos Cano, Marta Cuadros and Pedro P. Medina
    Citation: Molecular Cancer 2024 23:42
  24. Current treatment guidelines refer to small cell lung cancer (SCLC), one of the deadliest human malignancies, as a homogeneous disease. Accordingly, SCLC therapy comprises chemoradiation with or without immuno...

    Authors: Anna Solta, Büsra Ernhofer, Kristiina Boettiger, Zsolt Megyesfalvi, Simon Heeke, Mir Alireza Hoda, Christian Lang, Clemens Aigner, Fred R. Hirsch, Karin Schelch and Balazs Döme
    Citation: Molecular Cancer 2024 23:41
  25. Finding effective therapeutic targets to treat NRAS-mutated melanoma remains a challenge. Long non-coding RNAs (lncRNAs) recently emerged as essential regulators of tumorigenesis. Using a discovery approach co...

    Authors: Valentin Feichtenschlager, Linan Chen, Yixuan James Zheng, Wilson Ho, Martina Sanlorenzo, Igor Vujic, Eleanor Fewings, Albert Lee, Christopher Chen, Ciara Callanan, Kevin Lin, Tiange Qu, Dasha Hohlova, Marin Vujic, Yeonjoo Hwang, Kevin Lai…
    Citation: Molecular Cancer 2024 23:40
  26. Focal adhesion signaling involving receptor tyrosine kinases (RTK) and integrins co-controls cancer cell survival and therapy resistance. However, co-dependencies between these receptors and therapeutically ex...

    Authors: Felix Broghammer, Irina Korovina, Mahesh Gouda, Martina Celotti, Johan van Es, Inga Lange, Cornelia Brunner, Jovan Mircetic, Robert P. Coppes, Olivier Gires, Andreas Dahl, Michael Seifert and Nils Cordes
    Citation: Molecular Cancer 2024 23:39
  27. Most soft-tissue sarcomas (STS) exhibit an immunosuppressive tumor microenvironment (TME), leading to resistance against immune checkpoint inhibitors (ICIs) and limited therapeutic response. Preclinical data s...

    Authors: Maud Toulmonde, Jean-Philippe Guegan, Mariella Spalato-Ceruso, Florent Peyraud, Michèle Kind, Lucile Vanhersecke, François Le Loarer, Raul Perret, Coralie Cantarel, Carine Bellera, Alban Bessede and Antoine Italiano
    Citation: Molecular Cancer 2024 23:38
  28. Soft tissue sarcomas (STS) are diverse mesenchymal tumors with few therapeutic options in advanced stages. Trabectedin has global approval for treating STS patients resistant to anthracycline-based regimens. R...

    Authors: Cheng-Ming Sun, Maud Toulmonde, Mariella Spalato-Ceruso, Florent Peyraud, Alban Bessede, Michèle Kind, Sophie Cousin, Xavier Buy, Jean Palussiere, Antoine Bougouin, Catherine Sautès-Fridman, Hervé Wolf Fridman, Marina Pulido and Antoine Italiano
    Citation: Molecular Cancer 2024 23:37
  29. T-cell lymphoma is a highly invasive tumor with significant heterogeneity. Invasive tissue biopsy is the gold standard for acquiring molecular data and categorizing lymphoma patients into genetic subtypes. How...

    Authors: Zongyao Huang, Yao Fu, Hong Yang, Yehan Zhou, Min Shi, Qingyun Li, Weiping Liu, Junheng Liang, Liuqing Zhu, Sheng Qin, Huangming Hong and Yang Liu
    Citation: Molecular Cancer 2024 23:36
  30. circular RNAs (circRNAs) have been reported to exert important effects in the progression of numerous cancers. However, the functions of circRNAs in intrahepatic cholangiocarcinoma (ICC) are still unclear.

    Authors: Shuochen Liu, Yirui Wang, Tianlin Wang, Kuangheng Shi, Shilong Fan, Chang Li, Ruixiang Chen, Jifei Wang, Wangjie Jiang, Yaodong Zhang, Yananlan Chen, Xiao Xu, Yue Yu, Changxian Li and Xiangcheng Li
    Citation: Molecular Cancer 2024 23:35
  31. Clear cell renal cell carcinoma (ccRCC) is the most prevalent kidney cancer with high aggressive phenotype and poor prognosis. Accumulating evidence suggests that circRNAs have been identified as pivotal media...

    Authors: Bo Huang, Junwu Ren, Qiang Ma, Feifei Yang, Xiaojuan Pan, Yuying Zhang, Yuying Liu, Cong Wang, Dawei Zhang, Ling Wei, Lingyu Ran, Hongwen Zhao, Ce Liang, Xiaolin Wang, Shiming Wang, Haiping Li…
    Citation: Molecular Cancer 2024 23:34
  32. Circular RNAs are highly stable regulatory RNAs that have been increasingly associated with tumorigenesis and progression. However, the role of many circRNAs in triple-negative breast cancer (TNBC) and the rel...

    Authors: Chuanpeng Zhang, Ziyi Yu, Susu Yang, Yitao Liu, Jiangni Song, Juan Mao, Minghui Li and Yi Zhao
    Citation: Molecular Cancer 2024 23:33
  33. the problem in early diagnosis of sporadic cancer is understanding the individual’s risk to develop disease. In response to this need, global scientific research is focusing on developing predictive models bas...

    Authors: Natalia Malara, Maria Laura Coluccio, Fabiana Grillo, Teresa Ferrazzo, Nastassia C. Garo, Giuseppe Donato, Annamaria Lavecchia, Franco Fulciniti, Anna Sapino, Eliano Cascardi, Antonella Pellegrini, Prassede Foxi, Cesare Furlanello, Giovanni Negri, Guido Fadda, Arrigo Capitanio…
    Citation: Molecular Cancer 2024 23:32
  34. Minimally invasive testing is essential for early cancer detection, impacting patient survival rates significantly. Our study aimed to establish a pioneering cell-free immune-related miRNAs (cf-IRmiRNAs) signa...

    Authors: Peng Wu, Chaoqi Zhang, Xiaoya Tang, Dongyu Li, Guochao Zhang, Xiaohui Zi, Jingjing Liu, Enzhi Yin, Jiapeng Zhao, Pan Wang, Le Wang, Ruirui Li, Yue Wu, Nan Sun and Jie He
    Citation: Molecular Cancer 2024 23:31
  35. Bladder cancer ranks as the 10th most common cancer worldwide, with deteriorating prognosis as the disease advances. While immune checkpoint inhibitors (ICIs) have shown promise in clinical therapy in both ope...

    Authors: Tianlei Xie, Shan Peng, Shujun Liu, Minghao Zheng, Wenli Diao, Meng Ding, Yao Fu, Hongqian Guo, Wei Zhao and Junlong Zhuang
    Citation: Molecular Cancer 2024 23:30
  36. Current diagnostics for the detection of pancreato-biliary cancers (PBCs) need to be optimized. We therefore propose that methylated cell-free DNA (cfDNA) derived from non-invasive liquid biopsies serves as a ...

    Authors: Christina Hartwig, Jan Müller, Hagen Klett, Dina Kouhestani, Anke Mittelstädt, Anna Anthuber, Paul David, Maximilian Brunner, Anne Jacobsen, Karolina Glanz, Izabela Swierzy, Lotta Roßdeutsch, Bettina Klösch, Robert Grützmann, Timo Wittenberger, Kai Sohn…
    Citation: Molecular Cancer 2024 23:28
  37. Pancreatic cancer (PC) is an extremely malignant tumor with low survival rate. Effective biomarkers and therapeutic targets for PC are lacking. The roles of circular RNAs (circRNAs) in cancers have been explor...

    Authors: Hao Yuan, Chuang Chen, Haonan Li, Gexi Qu, Luyao Chen, Yaxing Liu, Yufeng Zhang, Qiang Zhao, Changhong Lian, Aifang Ji, Xuedong Hou, Xinjian Liu, Kuirong Jiang, Yi Zhu and Yuan He
    Citation: Molecular Cancer 2024 23:27
  38. Over the past three decades, considerable efforts have been expended on understanding the Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathway in leukemia, following the i...

    Authors: Dong Liang, Qiaoli Wang, Wenbiao Zhang, Hailin Tang, Cailu Song, Zhimin Yan, Yang Liang and Hua Wang
    Citation: Molecular Cancer 2024 23:25
  39. Colorectal cancer (CRC) is a major cause of cancer-related deaths worldwide, and chemoresistance is a major obstacle in its treatment. Despite advances in therapy, the molecular mechanism underlying chemoresis...

    Authors: Zehua Bian, Fan Yang, Peiwen Xu, Ge Gao, Chunyu Yang, Yulin Cao, Surui Yao, Xue Wang, Yuan Yin, Bojian Fei and Zhaohui Huang
    Citation: Molecular Cancer 2024 23:23
  40. Eukaryotic cells engage in autophagy, an internal process of self-degradation through lysosomes. Autophagy can be classified as selective or non-selective depending on the way it chooses to degrade substrates....

    Authors: Jiaxi Liu, Yongya Wu, Sha Meng, Ping Xu, Shutong Li, Yong Li, Xiuying Hu, Liang Ouyang and Guan Wang
    Citation: Molecular Cancer 2024 23:22
  41. The ATM kinase constitutes a master regulatory hub of DNA damage and activates the p53 response pathway by phosphorylating the MDM2 protein, which develops an affinity for the p53 mRNA secondary structure. Disrup...

    Authors: Konstantinos Karakostis, Laurence Malbert-Colas, Aikaterini Thermou, Borek Vojtesek and Robin Fåhraeus
    Citation: Molecular Cancer 2024 23:21
  42. The incidence of nasopharyngeal carcinoma (NPC) exhibits significant variations across different ethnic groups and geographical regions, with Southeast Asia and North Africa being endemic areas. Of note, Epste...

    Authors: Huai Liu, Ling Tang, Yanxian Li, Wenji Xie, Ling Zhang, Hailin Tang, Tengfei Xiao, Hongmin Yang, Wangning Gu, Hui Wang and Pan Chen
    Citation: Molecular Cancer 2024 23:20
  43. Heat shock proteins play crucial roles in various biochemical processes, encompassing protein folding and translocation. HSP90B1, a conserved member of the heat shock protein family, growing evidences have dem...

    Authors: Xiaoliang Huang, Weiming Zhang, Na Yang, Yujie Zhang, Tianyu Qin, Hanyi Ruan, Yan Zhang, Chao Tian, Xianwei Mo, Weizhong Tang, Jungang Liu and Beibei Zhang
    Citation: Molecular Cancer 2024 23:19
  44. The production and release of tumor-derived small extracellular vesicles (TDSEVs) from cancerous cells play a pivotal role in the propagation of cancer, through genetic and biological communication with health...

    Authors: Chi Zhang, Chaoying Qin, Saikat Dewanjee, Hiranmoy Bhattacharya, Pratik Chakraborty, Niraj Kumar Jha, Moumita Gangopadhyay, Saurabh Kumar Jha and Qing Liu
    Citation: Molecular Cancer 2024 23:18
  45. Authors: Lei Xu, Xiao Ma, Xiuzhong Zhang, Chong Zhang, Yi Zhang, Shuai Gong, Nai Wu, Peng Zhang, Xinyu Feng, Jiaxuan Guo, Mengmeng Zhao, Zeqiang Ren and Pengbo Zhang
    Citation: Molecular Cancer 2024 23:16

    The original article was published in Molecular Cancer 2023 22:195

Annual Journal Metrics

  • 2022 Citation Impact
    37.3 - 2-year Impact Factor
    33.1 - 5-year Impact Factor
    5.740 - SNIP (Source Normalized Impact per Paper)
    8.703 - SJR (SCImago Journal Rank)

    2023 Speed
    5 days submission to first editorial decision for all manuscripts (Median)
    91 days submission to accept (Median)

    2023 Usage 
    3,569,666 downloads
    2,070 Altmetric mentions